MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer - a randomized, doubleblind, placebo-controlled, phase 3 study

被引：0

作者：

Al-Batran, S. -E ^{[1
]}

Janjigian, Y. ^{[2
]}

Van Cutsem, E. ^{[3
,4
]}

Muro, K. ^{[5
]}

Wainberg, Z. ^{[6
]}

Hyung, W. J. ^{[7
]}

Molena, D. ^{[8
]}

Evans, B. ^{[8
]}

Ruscica, D. ^{[9
]}

Robbins, S. H. ^{[8
]}

Negro, A. ^{[8
]}

Tabernero, J. ^{[10
]}

机构：

[1] Univ Canc Ctr, Frankfurt, Germany

[2] Mem Sloan Kettering, New York, NY USA

[3] Univ Hosp Leuven, Leuven, Belgium

[4] KULeuven, Leuven, Belgium

[5] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan

[6] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[7] Yonsei Univ, Coll Med, Seoul, South Korea

[8] AstraZeneca, Gaithersburg, MD USA

[9] AstraZeneca, Cambridge, England

[10] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2021年 / 44卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ep507

引用

页码：218 / 218

页数：1

共 50 条

[1] MATTERHORN: A phase 3 study of efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer
Janjigian, Y.
Van Cutsem, E.
Muro, K.
Wainberg, Z.
Al-Batran, S.
Hyung, W.
Molena, D.
Evans, B.
Ruscica, D.
Robbins, S.
Negro, A.
Tabernero, J.
ANNALS OF ONCOLOGY, 2021, 32 : S118 - S118
[2] MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer - a randomized, double-blind, placebo-controlled, phase 3 study
Janjigian, Yelena
Van Cutsem, Eric
Muro, Kei
Wainberg, Zev
Al-Batran, Salah-Eddin
Hyung, Woo Jin
Molena, Daniela
Evans, Brent
Ruscica, Dario
Robbins, Scott H.
Negro, Alejandra
Tabernero, Josep
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 94 - 94
[3] MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer-A randomized, double-blind, placebo-controlled, phase 3 study.
Janjigian, Yelena Y.
Van Cutsem, Eric
Muro, Kei
Wainberg, Zev A.
Al-Batran, Salah-Eddin
Hyung, Woo Jin
Molena, Daniela
Evans, Brent
Ruscica, Dario
Robbins, Scott H.
Negro, Alejandra
Tabernero, Josep
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[4] MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer
Janjigian, Yelena Y.
Van Cutsem, Eric
Muro, Kei
Wainberg, Zev
Al-Batran, Salah-Eddin
Hyung, Woo Jin
Molena, Daniela
Marcovitz, Michelle
Ruscica, Dario
Robbins, Scott H.
Negro, Alejandra
Tabernero, Josep
FUTURE ONCOLOGY, 2022, 18 (20) : 2465 - 2473
[5] Pathological complete response to FLOT chemotherapy with/without durvalumab in resectable gastric and gastroesophageal junction cancer:subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study
Janjigian, Yelena Y.
Al-Batran, Salah-Eddin
Wainberg, Zen A.
Van Cutsem, Eric
Molena, Daniela
Muro, Kei
Hyung, Woo Jin
Wyrwicz, Lucjan
Oh, Do-Youn
Omori, Takeshi
Moehler, Markus
Garrido, Marcelo
Oliveira, Sulene C. S.
Liberman, Moishe
Oliden, Victor C.
Bilici, Mehmet
Kurland, John
Xynos, Ioannis
Mann, Helan
Tabernero, Josep
ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (01) : S44 - S45
[6] PATHOLOGICAL COMPLETE RESPONSE (PCR) TO DURVALUMAB PLUS 5FLUOROURACIL, LEUCOVORIN, OXALIPLATIN AND DOCETAXEL (FLOT) IN RESECTABLE GASTRIC AND GASTROESOPHAGEAL JUNCTION CANCER (GC/GEJC): INTERIM RESULTS OF THE GLOBAL, PHASE 3 MATTERHORN STUDY
Molena, Daniela
Janjigian, Yelena
Al-Batran, Salah-Eddin
Wainberg, Zev A.
Van Cutsem, Eric
Muro, Kei
Hyung, Woo J.
Wyrwicz, Lucjan
Oh, Do-Youn
Omori, Takeshi
Moehler, Markus
Garrido, Marcelo
Oliveira, Sulene C.
Liberman, Moishe
Oliden, Victor Castro
Bilici, Mehmet
Kurland, John F.
Xynos, Ioannis
Mann, Helen
Tabernero, Josep
GASTROENTEROLOGY, 2024, 166 (05) : S996 - S996
[7] Safety and efficacy of aif on knee ostcoarthritis patients: Doubleblind, randomized placebo-controlled study
Park, Sung-Hoon
Kim, Seong-Kyu
Choe, Jung-Yoon
Chung, Won Tae
ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S483 - S483
[8] KEYNOTE-585: randomized, phase 3 study of chemotherapy plus pembrolizumab vs chemotherapy plus placebo as neoadjuvant/adjuvant treatment for patients with gastric or gastroesophageal junction (G/GEJ) cancer
Bang, Yung-Jue
Van Cutsem, Eric
Fuchs, Charles
Ohtsu, Atsushi
Tabernero, Josep
Ilson, David
Hyung, Woo Jin
Strong, Vivian
Goetze, Thorsten
Yoshikawa, Takaki
Tang, Laura
Sun, Linda
Hasan, Aisha
Koshiji, Minori
Shitara, Kohei
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
[9] Efficacy and Safety of Vonoprazan in Patients With Nonerosive Gastroesophageal Reflux Disease: A Randomized, Placebo-Controlled, Phase 3 Study
Kinoshita, Yoshikazu
Sakurai, Yuuichi
Takabayashi, Nobuyoshi
Kudou, Kentaro
Araki, Takahiro
Miyagi, Takuya
Iwakiri, Katsuhiko
Ashida, Kiyoshi
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2019, 10
[10] Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
Moehler, Markus
Janjigian, Yelena
Al-Batran, Salah-Eddin
Wainberg, Zev
Van Cutsem, Eric
Molena, Daniela
Muro, Kei
Hyung, Woo Jin
Wyrwicz, Lucjan
Oh, Do-Youn
Omori, Takeshi
Garrido, Marcelo
Sousa, Oliveira Sulene Cunha
Liberman, Moishe
Oliden, Victor Castro
Bilici, Mehmet
Kurland, John F.
Xynos, Ioannis
Mann, Helen
Tabernero, Josep
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 229 - 229

← 1 2 3 4 5 →